|
[1]
|
李辛, 吕祥, 梁志江. 不同透析方式对残余肾功能的影响及其与预后的关系研究[J]. 中国医学工程, 2018, 26(12): 29-32.
|
|
[2]
|
任伟, 兰雷. 透析病人保护残余肾功能的重要性[J]. 国外医学(老年医学分册), 2007, 28(4): 185-188.
|
|
[3]
|
孙春晓, 郭兆安. 慢性肾脏病血脂代谢紊乱的影响因素及其机制的研究进展[J]. 中国中西医结合肾病杂志, 2014, 15(6): 546-548.
|
|
[4]
|
刘爱英, 冯国徵, 孙秀丽. 血液透析与腹膜透析对终末期肾病患者血脂、氧化应激及炎症因子的影响[J]. 中国煤炭工业医学杂志, 2020, 23(1): 57-61.
|
|
[5]
|
吴娜. 第一年残余肾功能下降速率和腹膜透析患者死亡风险的研究[D]: [硕士学位论文]. 广州: 南方医科大学, 2022.
|
|
[6]
|
张琪琦, 安惠霞, 姜国涛, 等. 高血脂对腹膜透析患者的残余肾功能影响[J]. 中国中西医结合肾病杂志, 2007, 8(8): 466-468.
|
|
[7]
|
韩庆烽, 郑丹侠, 齐颖, 等. 腹膜透析病人残余肾功能减退的影响因素[J]. 北京医科大学学报, 2000, 32(1): 87, 89.
|
|
[8]
|
赵飞, 潘志铣, 曾瑞坤, 等. 血液透析患者残余肾功能与血压的相关性分析[J]. 数理医药学杂志, 2020, 33(7): 957-959.
|
|
[9]
|
Schwarz, U., Buzello, M., Ritz, E., Stein, G., Raabe, G., Wiest, G., et al. (2000) Morphology of Coronary Atherosclerotic Lesions in Patients with End-Stage Renal Failure. Nephrology Dialysis Transplantation, 15, 218-223. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Campese, V.M. (2014) Dyslipidemia and Progression of Kidney Disease: Role of Lipid-Lowering Drugs. Clinical and Experimental Nephrology, 18, 291-295. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Schaeffner, E.S., Kurth, T., Curhan, G.C., Glynn, R.J., Rexrode, K.M., Baigent, C., et al. (2003) Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men. Journal of the American Society of Nephrology, 14, 2084-2091. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Hovind, P., Rossing, P., Tarnow, L., Smidt, U.M. and Parving, H. (2001) Remission and Regression in the Nephropathy of Type 1 Diabetes When Blood Pressure Is Controlled Aggressively11see Editorial by Steffes, P. 378. Kidney International, 60, 277-283. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
孟梅霞, 张莉, 傅艳平, 等. 慢性肾脏病与血脂异常关系的调查研究[J]. 陕西医学杂志, 2014(9): 1157-1159.
|
|
[14]
|
Abrass, C.K. (2004) Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal Disease. American Journal of Nephrology, 24, 46-53. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Chen, S., Hung, C., Kuo, M., Lee, J., Chiu, Y., Chang, J., et al. (2013) Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease. PLOS ONE, 8, e55643. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
李晓燕. CKD高脂血症患者中医证候特点的研究[D]: [硕士学位论文]. 济南: 山东中医药大学, 2012.
|
|
[17]
|
Massy, Z.A., Kim, Y., Guijarro, C., Kasiske, B.L., Keane, W.F. and O’Donnell, M.P. (2000) Low-Density Lipoprotein-Induced Expression of Interleukin-6, a Marker of Human Mesangial Cell Inflammation: Effects of Oxidation and Modulation by Lovastatin. Biochemical and Biophysical Research Communications, 267, 536-540. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Wagner, A.H., Köhler, T., Rückschloss, U., Just, I. and Hecker, M. (2000) Improvement of Nitric Oxide–dependent Vasodilatation by Hmg-Coa Reductase Inhibitors through Attenuation of Endothelial Superoxide Anion Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 61-69. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Ruan, X.Z., Moorhead, J.F., Tao, J.L., Ma, K.L., Wheeler, D.C., Powis, S.H., et al. (2006) Mechanisms of Dysregulation of Low-Density Lipoprotein Receptor Expression in Vascular Smooth Muscle Cells by Inflammatory Cytokines. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1150-1155. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Rovin, B.H. and Tan, L.C. (1993) LDL Stimulates Mesangial Fibronectin Production and Chemoattractant Expression. Kidney International, 43, 218-225. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Bianchi, S., Bigazzi, R., Caiazza, A. and Campese, V.M. (2003) A Controlled, Prospective Study of the Effects of Atorvastatin on Proteinuria and Progression of Kidney Disease. American Journal of Kidney Diseases, 41, 565-570. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Bussolati, B., Deregibus, M.C., Fonsato, V., Doublier, S., Spatola, T., Procida, S., et al. (2005) Statins Prevent Oxidized LDL-Induced Injury of Glomerular Podocytes by Activating the Phosphatidylinositol 3-Kinase/AKT-Signaling Pathway. Journal of the American Society of Nephrology, 16, 1936-1947. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Kagan, A., Elimalech, E., Lerner, Z., Fink, A. and Bar-Khayim, Y. (1997) Residual Renal Function Affects Lipid Profile in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 17, 243-249. [Google Scholar] [CrossRef]
|
|
[24]
|
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J.F.E., Ruf, G., et al. (2005) Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. New England Journal of Medicine, 353, 238-248. [Google Scholar] [CrossRef] [PubMed]
|